SOURCE: Oncology Med, Inc.

March 20, 2008 07:05 ET

Oncology Med Executes Its Second Contract for Its New Prostate Cancer Brachytherapy Program With Ambulatory Surgery Center Located in the Northeast

Contract Projected to Be Worth $ 300,000.00 Over the Next 12 Months

PITTSBURGH, PA--(Marketwire - March 20, 2008) - Oncology Med, Inc. (PINKSHEETS: ONCO) announced that it has executed its second contract for its new brachytherapy program with an ambulatory surgical center located in the Northeast. Brachytherapy is the treatment of prostate cancer through the implantation of radioactive seeds. It is projected that the contract will add $ 300,000.00 of revenue over the next 12 months thereby increasing the Company's run rate by 15% over that same period.

Dr. William J. Walker, chairman of Oncology Med, Inc., stated, "I am extremely pleased with the execution of our second contract for our new prostate cancer brachytherapy program. As we mentioned in our press release dated February 12, 2008, the new rules and changes made to reimbursement policies for ambulatory surgical centers by the Center for Medicare and Medicaid Services will increase the demand for our services to these medical facilities. This second contract is an additional endorsement of the tremendous opportunity available to us and I believe there will be several additional contracts we may enter into in the near future."

About Oncology Med, Inc.

Oncology Med is a public company engaged in the fulfillment of services related to the treatment of various cancers. It currently provides analysis and design of radiation treatment plans in order for radiation oncologists to administer radiation plans to cancer patients. Current services facilitate radiation treatment programs ranging from external beam radiation to more advanced radiation treatment technologies.

More information about Oncology Med, Inc. can be found at www.oncologymed.com.

NOTE: This press release may contain "forward-looking statements." In some cases, you can identify forward-looking statements by terminology such as "may," "will," "should," "could," "expects," "plans," "intends," "anticipates," "believes," "estimates," "predicts," "potential," "continue" or the negative of such terms and other comparable terminology. These forward-looking statements include, without limitation, statements about our market opportunity, our strategies, competition, expected activities and expenditures as we pursue our business plan, and the adequacy of our available cash resources. Although we believe that the expectations reflected in any forward-looking statements are reasonable, we cannot guarantee future results, levels of activity, performance or achievements. Actual results may differ materially from the predictions discussed in these forward-looking statements. Changes in the circumstances upon which we base our predictions and/or forward-looking statements could materially affect our actual results.

Contact Information

  • For information, please contact:
    Oncology Med, Inc.
    Email Contact